Tanimilast, A Novel Inhaled Pde4 Inhibitor for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease

医学 罗氟司特 慢性阻塞性肺病 哮喘 慢性支气管炎 重症监护医学 内科学
作者
Fabrizio Facchinetti,Maurizio Civelli,Dave Singh,Alberto Papi,Aida Emirova,Mirco Govoni
出处
期刊:Frontiers in Pharmacology [Frontiers Media]
卷期号:12: 740803-740803 被引量:32
标识
DOI:10.3389/fphar.2021.740803
摘要

Chronic respiratory diseases are the third leading cause of death, behind cardiovascular diseases and cancer, affecting approximately 550 million of people all over the world. Most of the chronic respiratory diseases are attributable to asthma and chronic obstructive pulmonary disease (COPD) with this latter being the major cause of deaths. Despite differences in etiology and symptoms, a common feature of asthma and COPD is an underlying degree of airways inflammation. The nature and severity of this inflammation might differ between and within different respiratory conditions and pharmacological anti-inflammatory treatments are unlikely to be effective in all patients. A precision medicine approach is needed to selectively target patients to increase the chance of therapeutic success. Inhibitors of the phosphodiesterase 4 (PDE4) enzyme like the oral PDE4 inhibitor roflumilast have shown a potential to reduce inflammatory-mediated processes and the frequency of exacerbations in certain groups of COPD patients with a chronic bronchitis phenotype. However, roflumilast use is dampened by class related side effects as nausea, diarrhea, weight loss and abdominal pain, resulting in both substantial treatment discontinuation in clinical practice and withdrawal from clinical trials. This has prompted the search for PDE4 inhibitors to be given by inhalation to reduce the systemic exposure (and thus optimize the systemic safety) and maximize the therapeutic effect in the lung. Tanimilast (international non-proprietary name of CHF6001) is a novel highly potent and selective inhaled PDE4 inhibitor with proven anti-inflammatory properties in various inflammatory cells, including leukocytes derived from asthma and COPD patients, as well as in experimental rodent models of pulmonary inflammation. Inhaled tanimilast has reached phase III clinical development by showing promising pharmacodynamic results associated with a good tolerability and safety profile, with no evidence of PDE4 inhibitors class-related side effects. In this review we will discuss the main outcomes of preclinical and clinical studies conducted during tanimilast development, with particular emphasis on the characterization of the pharmacodynamic profile that led to the identification of target populations with increased therapeutic potential in inflammatory respiratory diseases.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
jias发布了新的文献求助10
刚刚
刚刚
无处不在发布了新的文献求助10
刚刚
Akim应助科研通管家采纳,获得10
1秒前
orixero应助科研通管家采纳,获得10
1秒前
1秒前
小二郎应助科研通管家采纳,获得10
1秒前
国泰民安发布了新的文献求助10
1秒前
Hello应助科研通管家采纳,获得10
1秒前
竹马子完成签到,获得积分10
1秒前
Owen应助科研通管家采纳,获得30
1秒前
丘比特应助科研通管家采纳,获得10
1秒前
科目三应助科研通管家采纳,获得10
2秒前
在水一方应助科研通管家采纳,获得10
2秒前
LiLy完成签到,获得积分10
2秒前
2秒前
Ava应助科研通管家采纳,获得10
2秒前
明天见发布了新的文献求助10
2秒前
2秒前
bkagyin应助科研通管家采纳,获得10
2秒前
Ava应助科研通管家采纳,获得10
2秒前
Hello应助科研通管家采纳,获得10
2秒前
粗犷的抽屉完成签到,获得积分10
2秒前
华仔应助科研通管家采纳,获得10
2秒前
殷润琳完成签到,获得积分10
2秒前
汉堡包应助科研通管家采纳,获得10
3秒前
炙热睿渊发布了新的文献求助10
3秒前
ding应助球球采纳,获得10
3秒前
打打应助科研通管家采纳,获得10
3秒前
3秒前
dianeluo完成签到,获得积分10
3秒前
天天快乐应助科研通管家采纳,获得10
3秒前
叫哥神手发布了新的文献求助10
3秒前
英姑应助科研通管家采纳,获得10
3秒前
无花果应助科研通管家采纳,获得10
3秒前
CodeCraft应助科研通管家采纳,获得10
3秒前
4秒前
爆米花应助科研通管家采纳,获得10
4秒前
共享精神应助科研通管家采纳,获得10
4秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Fermented Coffee Market 2000
PARLOC2001: The update of loss containment data for offshore pipelines 500
Critical Thinking: Tools for Taking Charge of Your Learning and Your Life 4th Edition 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 500
A Manual for the Identification of Plant Seeds and Fruits : Second revised edition 500
Constitutional and Administrative Law 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5261749
求助须知:如何正确求助?哪些是违规求助? 4422906
关于积分的说明 13767729
捐赠科研通 4297318
什么是DOI,文献DOI怎么找? 2357911
邀请新用户注册赠送积分活动 1354280
关于科研通互助平台的介绍 1315383